A Roundtable Discussion on Complement 3 Glomerulopathy (C3G): Improving Diagnosis, Risk Stratification, and Therapeutic Strategies

Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by dysregulation of the alternative pathway (AP) of the complement cascade, either due to genetic variants or acquired humoral factors¹.  About 50% of patients with C3G progress to kidney failure within 10 years of diagnosis^2,6. Diagnosis and management are frequently delayed in part due to overlapping clinical presentations, histologic features, and underlying pathophysiologies.

This on-demand CME webinar will review illustrative patient cases, discussing consensus guideline treatment recommendations and the uncertainties, challenges, and considerations regarding the diagnosis and management of patients with C3G in clinical practice using an interactive roundtable conversation format.

Early Recognition and Management of Dupuytren's Contracture

This CME activity will provide a practical overview of Dupuytren’s contracture, a common hand pathology that is often first present in the primary care setting. The session will focus on recognizing key clinical features, performing effective diagnosis and screening in everyday practice, and understanding available treatment options ranging from observation and non-surgical interventions to surgical management. Emphasis will be placed on the role of the osteopathic internists in early detection, patient education, and timely referral to hand specialists when appropriate.

Exploring Biosimilars in Pediatric Psoriasis: Emerging Treatment Options

Biosimilars are complex biologic therapies derived from living organisms and developed to be highly similar to an FDA-approved reference product in structure, function, and clinical performance, without clinically meaningful differences in safety, purity, or potency. This activity will review current advancements in the understanding and clinical application of biosimilars for the management of psoriasis. Growing evidence supports their safety, efficacy, and real-world integration, highlighting biosimilars as cost-effective alternatives to originator biologics and important tools for expanding patient access to high-quality biologic treatments.

Highlights from ACEP - Severe Abdominal Pain: Could it be an Acute Porphyria Attack?

Patients with certain inherited metabolic disorders often arrive in the ED with porphyria-like attacks. To better understand AHP (acute hepatic porphyria) whose main acute presentations include severe abdominal pain, extensive neuropathy issues, disabling respiratory symptoms, tachycardia, vomiting, and more, patient cases will be reviewed covering these neurovisceral acute attacks, with recommended strategies for immediate patient treatment will be discussed.

Highlights from the EIM Annual Meeting: Acute Hepatic Porphyria in the ED – Spotting the Red Flags behind Severe Abdominal Pain

Acute hepatic porphyrias (AHPs) are rare, inherited metabolic disorders that can present severe, recurrent episodes of abdominal pain accompanied by a wide range of nonspecific gastrointestinal, neurologic, psychiatric, and autonomic symptoms. Because these manifestations often mimic more common conditions, patients frequently experience prolonged diagnostic delays, multiple healthcare encounters, and unnecessary procedures before an accurate diagnosis is established. Through a case-based discussion, faculty will review the clinical features that distinguish AHP from more common causes of abdominal pain, highlight key diagnostic clues and red flags, and discuss appropriate laboratory testing and referral pathways. This activity aims to support earlier diagnosis, reduce diagnostic delays, and improve outcomes for patients with this potentially life-threatening condition.

Hypophosphatasia (HPP): Proposed HPP International Working Group Criteria

Hypophosphatasia (HPP) is a progressive, debilitating and sometimes fatal metabolic bone disease caused by loss of function mutations in the ALPL gene.  Its clinical manifestations and severity of symptoms vary widely from patient to patient.

A multinational consortium of key opinion leaders, who are world specialists in hypophosphatasia (HPP), convened virtually during the past couple of years to recommend criteria for the diagnosis of HPP in children and adults, given that there are no formal diagnostic guidelines HPP. 

Our two presenters are co-authors of the Proposed Criteria and will offer a review of the criteria including the measurable factors or parameters used to determine them, consensus recommendations for clinical practice, and appropriate treatment. By providing practical information and tools to help healthcare professionals better understand the diagnostic process, patients can be diagnosed earlier and experience better disease management and quality of life.